Brought to you by 
Idenix partners HIV candidate, other NNRTIs with GSK; terminated
11 Dec 2015
Executive Summary
Idenix Pharmaceuticals (public infectious disease company majority owned by Novartis) has licensed GlaxoSmithKline exclusive worldwide rights to develop, manufacture, and sell a group of its non-nucleoside reverse transcriptase inhibitors (NNRTIs) including once-daily IDX899, in Phase II for HIV and AIDS.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Idenix partners HIV candidate, other NNRTIs with GSK; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice